Books by Subject


  • This annual report details NIH-supported and -conducted Alzheimer's disease research initiatives, objectives, and advances during calendar year 2014 and early 2015. New findings and investments described in this report are organized in categories determined by the Common Alzheimer Disease Research Ontology (CADRO) of the International Alzheimer's Disease Research Portfolio (IADRP).
  • 2010From: ProQuest Safari
    Timothy Kachinske, Judith Kachinske.
    Getting started as a Grant writer -- Finding and securing a Grant-writing position -- Expertise -- Research -- Managing relationships -- Writing -- Organizing information -- Queries and short proposals -- Proposals for projects, programs, or bricks and mortar -- Proposals for endowment support -- Federal Grants -- Managing Grant awards.
  • edited by Michael E. Hochman.
    PrintStatus: Not Checked OutLane Catalog Record
    Sect. 1: Preventive medicine -- Preventing diabetes: the diabetes prevention program -- A comparison of different dieting strategies -- Aspirin for the primary prevention of cardiovascular disease: the physician's health study and the women's health study -- Postmenopausal hormone therapy: the women's health initiative -- The European randomized study of screening for prostate cancer (ERSPC) -- The cochrane review of screening mammography -- The human papillomavirus vaccine: the future II trial -- Sect. 2: Internal medicine -- Arrhythmia suppression following myocardial infarction: the CASt trial -- Choosing first-line therapy for hypertension: the ALLHAT trial -- Statins in healthy patients with an elevated c-reactive protein: the JUPITER trial -- Rate control versus rhythm control for atrial fibrillation: the AFFIRM trial -- Lenient versus strict heart rate control for atrial fibrillation: the RACC II trial. -- Beta blockers for systolic heart failure: the MERIT-HF trial -- Initial treatment of stable coronary artery disease: the COURAGE trial -- Treating elevated blood sugar levels in patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) -- Intensive versus conservative blood sugar for patients with type 2 diabetes: the ACCORD trial -- The African American heart failure trial (A-HeFT) -- Early versus delayed antiretroviral therapy for patients with HIV: the NA-ACCORD study -- Early versus late initiation of dialysis: the IDEAL trial -- Early goal-directed therapy in sepsis -- Red cell transfusion in critically ill patients: the TRICC trial -- Pulmonary artery catheters in critically ill patients -- Step-up versus step-down therapy for dyspepsia: the DIAMOND trial -- Opioids for chronic noncancer pain -- Sect. 3: Surgery -- Perioperative beta blockers in noncardiac surgery: the POISE trial -- Cardiac stents versus coronary artery bypass surgery for severe coronary artery disease: the SYNTAX trial -- Carotid endarterectomy for asymptomatic carotid stenosis: the ACST trial -- A trial of arthroscopic knee surgery -- Surgery versus rehabilitation for chronic low back pain: the MRC spine stabilization trial -- Mastectomy versus lumpectomy for invasive breast cancer: the B-06 trial -- Long-term impact of bariatric surgery: the Swedish obese subjects study -- Sect. 4: Obstetrics -- The Canadian multicenter post-term pregnancy trial (CMPPT) -- Antepartum glucocorticoids in premature labor -- Sect. 5: Pediatrics -- Treatment of acute otitis media in children -- A trial of early ear tube placement in children with persistent otitis media -- Inhaled corticosteroids for mild persistent asthma: the START trial -- The multimodal treatment study of children with attention deficit/hyperactivity disorder (MTA) -- Measles, mumps, and rubella vaccination and autism -- Sect. 6: Radiology -- Magnetic resonance imaging for low back pain -- Screening for coronary artery disease in asymptomatic patients with diabetes: the DIAD study -- Diagnosing acute pulmonary embolism: the Christopher study -- Identifying children with low-risk head injuries who do not require computed tomography -- Sect. 7: Neurology and psychiatry -- Thrombolysis 3 to 4.5 hours after an acute ischemic stroke: the ECASS III trial -- Initial treatment of depression -- Behavioral versus pharmacological treatment for insomnia in the elderly -- Sect. 8: Systems-based practice -- The group health medical home demonstration -- A program to improve care coordination at hospital discharge: project RED -- Reducing catheter-related blood stream infections in the intensive care unit: the keystone ICU project -- Early palliative care in non-small-cell lung cancer -- Directly observed therapy for the treatment of tuberculosis in Baltimore.
  • 2012From: CRCnetBASE
    Richard Chin.
    1. Background -- 2. Conventional statistics -- 3. Statistics used in adaptive clinical trials -- 4. Specific requirements for adaptive trials -- 5. Adaptive randomization and allocation -- 6. Sample size reestimation -- 7. Traditional dosing -- 8. Adaptive dosing -- 9. Interim analysis and adaptive termination of study and study arms -- 10. Adaptive changes in study design and decision rules -- 11. Seamless designs and adaptive clinical trial conduct -- 12. Analysis and interpretation of results.
  • 2007Click LINK above for Print location/circulation status.
    2007From: CRCnetBASE
    Shein-Chung Chow, Mark Chang.
  • 2012From: CRCnetBASE
    Shein-Chung Chow, Mark Chang.
    Protocol amendment -- Adaptive randomization -- Adaptive hypotheses -- Adaptive dose-escalation trials -- Adaptive group sequential design -- Statistical tests for adaptive seamless designs -- Adaptive sample size adjustment -- Two-stage adaptive design -- Adaptive treatment switching -- Bayesian approach -- Biomarker adaptive trials -- Target clinical trials -- Sample size and power estimation -- Clinical trial simulation -- Regulatory perspectives : a review of FDA draft guidance.
  • 2012From: Thieme Book
    edited by Mohit Bhandari, Bernd Robioneck ; associate editor, Emil Schemitsch ; managing editor, Sheila Sprague ; with contributions by Volker Alt ... [et al.].
    1. Factorial Randomized Trials -- Summary -- Introduction -- Randomized clinical trial design strategies with multiple interventions -- Selecting a factorial randomized design -- Conclusion -- 2. Expertise-based randomized trials -- Summary -- Introduction -- Conventional RCT design -- Expertise-based RCT design -- Challenges of expertise-based RCTs -- Independent assessor -- Balanced and consecutive or random contributions to screening pool -- Perceived equivalence between practices -- Conclusion -- 3. Randomization systems and technology -- Summary -- Introduction -- Methods of patient allocation -- Other considerations -- Conclusion -- 4. Blinding and concealment -- Summary -- Introduction -- Concealment -- Blinding -- Conclusion -- 5. Composite outcome in orthopaedics: understanding the concepts -- Summary -- Introduction -- Rationale for use of a composite outcome -- Limitations of using composite outcomes -- Guidelines for creating a "good" composite outcome -- Reporting and interpreting composite outcomes -- Conclusion -- 6. Adjudication of outcomes-systems and approaches -- Summary -- Introduction -- Importance of adjudication -- Process of adjudication -- Existing methods of adjudication -- Web-based adjudication -- Conclusion -- 7. Subgroup analyses -- Summary -- Introduction -- Subgroup analysis defined -- Design of a subgroup analysis -- Reporting -- Interpretation -- Conclusion -- 8. Trial management-advance concepts and systems -- Summary -- Introduction -- Phases of clinical trials -- Common considerations in conducting a clinical trial -- Trial committees -- The search for funding -- Conclusion 9. Case-control studies -- Summary -- Introduction -- Definition of a case-control study -- Conclusion -- 10. Cohort studies -- Summary -- Introduction -- Cohort studies in the hierarchy of evidence -- Types of cohort study designs -- Methods for reducing confounding and assessing causality -- A checklist to evaluate or improve the strength of evidence -- Conclusion --; 11. Survey Design -- Summary -- Introduction -- Identifying a research question -- Survey development -- Survey design -- Using exiting surveys -- survey validataion -- Pilot testing -- Survey administration -- Ethical considerations -- Financial considerations -- Conclusion -- 12. Qualitative studies -- Summary -- Introduction -- What is qualitative research? -- How is qualitative research done? -- Conclusion -- 13. Economic analysis -- Summary -- Introduction -- Theoretical background -- Conducting health economics studies -- Conclusion -- 14. Literature searches -- Summary -- Introduction -- When to conduct a literature search -- How to conduct a literature search -- Study selection -- Assessing methodological quality of studies -- Data extraction and analysis -- Conclusion -- 15. Summary -- Introduction -- the P value does not assess the magnitude of a treatment effect -- The challenge of comparing results across studies -- Types of effect sizes -- Confidence intervals for effect sizes -- Use of effect size in meta-analysis -- Conclusion -- 16. Fixed effects versus random effects -- Summary -- Introduction -- the data pool: fixed effects versus random effects -- Deciding which model to use -- Conclusion -- 17. Heterogeneity -- Summary -- Introduction -- Heterogeneity defined -- Identifying heterogeneity -- Dealing with heterogeneity -- Conclusion -- 18. Uncovering publicatiion bias -- Summary -- Introduction -- Authors and publication bias -- Detecting and adjusting for publication bias -- Minimizing the effect of publication bias -- A possible solution: trial registers -- Conclusion -- 19. Statiecal pooling - programs and systems -- Summary -- Introduction -- Selectin the appropriate programs and systems: factors to consider --Review of programs and systems -- Types of programs and systems -- Recommendations -- Conclusion -- 20. Meta-analysis of observational studies -- Summary -- Introduction -- The observational data dilemma -- Conclusion -- 21. Meta-regression -- Summary -- Introduction -- Heterogeneity and meta-regression -- Meta-regression mechanics -- Interpreting a meta-regression -- Limitations of meta-regression -- Conclusion -- 22. Preparing a statistical analysis plan -- Summary -- Introduction -- Data management -- Statistical procedures -- Data safety and monitoring board -- Sample size -- Interim analysis -- Reports to investigators -- Sensitivity analysis -- Tables of presentation and publication -- Software -- Reporting guidelines -- General policies -- Privacy considerations -- Apendices -- What is in the literature about SAP? -- Conclusion --; 24. Survival analysis -- Summary -- Introduction -- Documenting time-to-event (survival) data -- the rationale for time-to-event (survival) analysis -- Methods for survival analysis -- Comparing groups -- Practical considerations in the desin of time-to-event studies -- Conclusion -- 25. Interim analyses in randomized trials -- Summary -- Introduction -- Interim analysis defined -- Design of an interim analysis -- Data monitoring committees -- Consequences of stopping early for benefit -- Conclusion -- 26. Conflicts of interest reporting -- Summary -- Introduction -- Legal implications -- Types of conflict of interest -- Who should disclose conflicts of interest? -- When must conflicts of interest be disclosed? -- Guidelines and recommendations for disclosure -- Why must personal financial interests be disclosed? -- Alternatives to disclosure policies -- Conclusion -- 27. Authorship-modern approaches and reporting -- Summary -- Introduction -- Academic stream -- Educational stream -- Industrial stream -- Popular media stream -- Conclusion -- 28. Randomized trials reporting checklists -- Summary -- Introduction -- Consort statement -- Nonpharmacological trials -- NPT extension to consort statement -- CLEAR NPT -- Conclusion -- 29. Observational studies reporting checklists -- Summary -- Introduction -- Checklist for observational studies: the STROBE statement -- Guide to investigators: how to used the STROBE statement -- The STROBE statement: explanations of checklist items -- Conclusion -- 30. Meta-analysis reporting checklists -- Summary -- Introduction -- Meta-analysis reporting checklists -- Conclusion -- Resources and contacts for surgical research -- Summary -- Introduction -- Mentorship -- Graduate programes -- Online courses -- Textbooks and journals -- Courses and workshops -- Contract research organizations -- Conclusion -- Glossary of terms.
  • 2014From: Springer
    Vijay C. Verma, Alan C. Gange, editors.
    In recent years there has been significant attention paid on the endophytic research by various groups working within this domain. Mutualistic endophytic microbes with an emphasis on the relatively understudied fungal endophytes are the focus of this special book. Plants are associated with micro-organisms: endophytic bacteria and fungi, which live inter- and intra-cellularly without inducing pathogenic symptoms, but have active biochemical and genetic interactions with their host. Endophytes play vital roles as plant growth promoters, biocontrol agents, biosurfactant producers, enzymes and secondary metabolite producers, as well as providing a new hidden repertoire of bioactive natural products with uses in pharmaceutical, agrochemical and other biotechnological applications. The increasing interest in endophytic research generates significant progress in our understanding of the host-endophyte relationship at molecular and genetic level. The bio-prospection of microbial endophytes has led to exciting possibilities for their biotechnological application as biocontrol agent, bioactive metabolites, and other useful traits. Apart from these virtues, the microbial endophytes may be adapted to the complex metabolism of many desired molecules that can be of significant industrial applications. These microbes can be a useful alternative for sustainable solutions for ecological control of pests and diseases, and can reduce the burden of excess of chemical fertilizers for this purpose. This book is an attempt to review the recent development in the understanding of microbial endophytes and their potential biotechnological applications. This is a collection of literature authored by noted researchers having signatory status in endophytic research and summarizes the development achieved so far, and future prospects for further research in this fascinating area of research.
  • 2007From: Springer
    Thorsten M. Buzug (ed.).
  • 2010From: CRCnetBASE
    edited by Cynthia M. Kuhn, George F. Koob.
    Advances in animal models of relapse for addiction research / Friedbert Weiss -- Application of chronic extracellular recording method to studies of cocaine self-administration : method and progress / Laura L. Peoples, Alexai V. Kravitz, and Karine Guillem -- Neurochemistry of addiction : monitoring essential neurotransmitters of addiction / Stefan G. Sandberg and Paul A. Garris -- Alcohol craving and relapse prediction : imaging studies / Andreas Heinz ... [et al.] -- Integrating behavioral and molecular approaches in mouse : self-administration studies / Danielle L. Graham and David W. Self -- Neuroeconomics : implications for understanding the neurobiology of addiction / Michael L. Platt ... [et al.].
  • Cheryl Iverson (chair) [and others].
    PrintStatus: Not Checked OutLane Catalog Record
    Types of articles -- Manuscript preparation -- References -- Visual presentation of data -- Ethical and legal considerations -- Editorial assessment and processing -- Grammar -- Punctuation -- Plurals -- Capitalization -- Correct and preferred usage -- Non-English words, phrases, and accent marks -- Medical indexes -- Abbreviations -- Nomenclature -- Eponyms -- Greek letters -- Units of measure -- Numbers and percentages -- Study design and statistics -- Mathematical composition -- Typography -- Manuscript editing and proofreading -- Glossary of publishing terms -- Resources.
    Also available: Print – 2007
  • 2009From: Springer
    David R. Gross.
    General principles of animal selection and normal physiological values -- Preanesthesia, anesthesia, chemical restraint, and the recognition and treatment of pain and distress -- Normal cardiac function parameters -- Measuring cardiac function -- Measuring vascular function and ventricular/arterial coupling dynamics -- Isolated heart preparations, problems, and pitfalls -- Cardiovascular effects of anesthetics, sedatives, postoperative analgesic agents, and other pharmaceuticals -- Naturally occurring and iatrogenic animal models of valvular, infectious, and arrhythmic cardiovascular disease -- Iatrogenic models of ischemic heart disease -- Iatrogenic, transgenic, and naturally occurring models of cardiomyopathy and heart failure -- Iatrogenic, congenic, and transgenic models of hypertension -- Naturally occurring, iatrogenic and transgenic models of atherosclerotic disease -- Animal models for the study of neurohumeral and central neural control of the cardiovascular system -- Other transgenic animal models used in cardiovascular studies
  • compiled by Anne-Laure Bourre.
    PrintStatus: Not Checked OutLane Catalog Record
  • 2014From: ProQuest Ebook Central
    Xiao-Hua Zhou, Chuan Zhou, Danping Liu, Xiaobo Ding.
    Missing data concepts and motivating examples -- Overview of methods for dealing with missing data -- Design considerations in the presence of missing data -- Crosssectional data methods -- Longitudinal data methods -- Survival analysis under ignorable missingness -- Nonignorable missingness -- Analysis of randomized clinical trials with noncompliance.
  • 2012From: ProQuest Ebook Central
    by Adam Gacek.
    The main sequence is comprised of approximately 200 entries dealing with almost all aspects of Arabic manuscript studies (codicology and paleography); includes appendices covering abbreviations, letterforms, såurah-headings, major reference works, and a guide to the description of manuscripts, as well as charts of major historical periods and dynasties.
  • 2008From: CRCnetBASE
    edited by Stephen A. Osmani, Gustavo H. Goldman.
  • 2017Limited to 1 simultaneous usersFrom: ProQuest Ebook Central
    edited by Margaret J. Foster, Sarah T. Jewell.
    This book guides librarians in defining and marketing their services, covering topics such as co-authorship, stakeholders, developing documentation and conducting the reference interview, systematic reviews standards, search strategy techniques, and best practices for reporting the findings.
  • Eric Tatt Wei Ho.
    The fruit fly, Drosophila melanogaster, is a key model species for biological research. Trained humans can manipulate, inspect and dissect individual flies, but these operations are often rate-limiting bottlenecks for screening and experimentation. Here I present a high-speed, economical robot for handling non-anesthetized adult flies. Using machine vision the robot tracks a fly's thorax and gently grabs it ~400 ms after targeting. The robot can then translate and rotate the picked fly, inspect its phenotype, dissect or release it, and thereby rapidly prepare multiple flies sequentially for a wide range of experimental formats. In one illustration, the robot restrained flies and dissected the cuticle to permit two-photon imaging of neural dynamics. In another, the robot sorted flies by sex. The robot's tireless capacity for accurate, repeatable manipulations will enable experiments and biotechnology applications that would otherwise be totally infeasible, especially those requiring high-throughput capture, testing and assessment of individual fly attributes.
  • 2017From: ScienceDirect
    edited by Morteza Jalali, Francesca Y.L. Saldanha, Mehdi Jalali ; foreword by Dame Sally Davies.
  • Juliet Corbin, International Institute for Qualitative Methodology, Anselm Strauss.
    PrintStatus: Not Checked OutLane Catalog Record
    Inspiration and background -- Theoretical foundations -- Practical considerations for getting started -- Prelude to analysis -- Strategies for qualitative data analysis -- Memos and diagrams -- Theoretical sampling -- Context -- Process -- Techniques for achieving theoretical integration -- The use of computer programs in qualitative data analysis -- Open coding: identifying concepts -- Developing concepts in terms of their properties and dimensions -- Analyzing data for context -- Bringing process into the analysis -- Integrating categories -- Writing theses, monographs, and dissertations, and giving talks -- About your research -- Criteria for evaluation -- Student questions and answers.
  • 2008From: SAGE
    Juliet Corbin and Anselm Strauss.
    Introduction -- Practical considerations -- Prelude to analysis -- Strategies for qualitative data analysis -- Introduction to context, process and theoretical integration -- Memos and diagrams -- Theoretical sampling -- Analyzing data for concepts -- Elaborating the analysis -- Analyzing data for context -- Bringing process into the analysis -- Integrating categories -- Writing theses, monographs, and giving talks -- Criterion for evaluation -- Student questions and answers.
  • 2011From: CRCnetBASE
    Scott M. Berry, Bradley P. Carlin, J . Jack Lee, and Peter Müller
    Chapter 1. Statistical approaches for clinical trials -- Chapter 2. Basics of Bayesian inference -- Chapter 3. Phase I studies -- Chapter 4. Phase II studies -- Chapter 5. Phase III studies -- Chapter 6. Special topics.
  • 2009From: CRCnetBASE
    Lyle D. Broemeling.
    Chapter 1. Introduction to Agreement -- Chapter 2. Bayesian Methods of Agreement for Two Raters -- Chapter 3. More than Two Raters -- Chapter 4. Agreement and Correlated Observations -- Chapter 5. Modeling Patterns of Agreement -- Chapter 6. Agreement with Quantitative Scores -- Chapter 7. Sample Sizes for Agreement Studies.
  • Brianna Rego.
    In 1952, the largest manufacturer of cigarettes, Philip Morris, founded a Department of Research and Development (R& D) that would ultimately elevate the company to its dominating role in the tobacco landscape. As revealed through internal industry documents available online and released through litigation, this study highlights both the role of scientific research in a controversial industry, and the role of individual researchers in the unbridled growth of Big Tobacco during the second half of the twentieth century. Despite extensive research, industry results were rarely published and never without extensive scrutiny by industry executives and lawyers. This scientific silence is in stark contrast to the industry's public stance of denying the health hazards of smoking. The extent to which the tobacco men understood the hazards of their products--and the specific details of several research projects on the dangers of smoking--are discussed. The history of the Department of Research at Philip Morris demonstrates that just as public concern was growing that smoking might be dangerous, the tobacco industry was actively pursuing research proving the very thing they were trying to convince the public was a non-issue: that smoking is harmful.
  • edited by Gesa E. Kirsch and Liz Rohan ; with a foreword by Lucille M. Schultz.
    PrintStatus: Not Checked OutLane Catalog Record
    Introduction: The role of serendipity, family connections, and cultural memory in historical research / Gesa E. Kirsch and Liz Rohan -- The accidental archivist : embracing chance and confusion in historical scholarship / David Gold -- Being on location : serendipity, place, and archival research / Gesa E. Kirsch -- Getting to know them : concerning research into four early women writers / Christine Mason Sutherland -- Making connections / Alicia Nitecki -- Traces of the familiar : family archives as primary source material / Wendy B. Sharer -- The biography of a graveyard / Ronald R. Stockton -- In a treeless landscape : a research narrative / Kathleen Wider -- My grandfather's trunk / Barry Rohan -- Colonial memory, colonial research : a preamble to a case study / Victor Villanueva -- Unbundling : archival research and Japanese American communal memory of U.S. Justice Department internment, 1941-45 / Gail Y. Okawa -- Mississippi on my mind / W. Ralph Eubanks -- Dreaming Charles Eastman : cultural memory, autobiography, and geography in indigenous rhetorical histories / Malea Powell -- Cultural memory and the lesbian archive / Kate Davy -- "I see dead people" : archive, crypt, and an argument for the researcher's sixth sense / Elizabeth (Betsy) Birmingham -- Stitching and writing a life / Liz Rohan -- When two stories collide, they catch fire / Anca Vlasopolos -- Stumbling in the archives : a tale of two novices / Lisa Mastrangelo and Barbara L'Eplattenier.
  • 2009From: ProQuest Ebook Central
    Sharyl J. Nass, Laura A. Levit, and Lawrence O. Gostin, editors ; Committee on Health Research and the Privacy of Health Information, the HIPAA Privacy Rule, Board on Health Sciences Policy, Board on Health Care Services.
    Introduction -- The value and importance of health information privacy -- The value, importance, and oversight of health research -- HIPAA, the privacy rule, and its application to health research -- Effect of the HIPAA privacy rule on health research -- A new framework for protecting privacy in health research.
  • 2010From: Springer
    Michael F. Ochs, John T. Casagrande, Ramana V. Davuluri, editors.
  • 2016From: Springer
    Seward B. Rutkove.
    Foreword -- PART 1: Basic considerations -- 1. So do you really want to pursue research? -- 2. What's in store: The brighter side of medical research -- 3. What's in store: The darker side of medical research -- 4. One degree of separation -- 5. Choosing and working with a mentor -- 6. Identifying a research niche you can call your own -- 7. Useful Definitions -- PART 2: Research Foundations and Structures -- 8. The Institutional Review Board: Do's, Don'ts, and Nevers... -- 9. Animal Care and Use Committees -- 10. Research beyond humans and vertebrates -- 11. Hiring Research Staff -- 12. Strategy and Tactics: Running a Successful Laboratory -- 13. Everything you ever wanted to know about collaboration Part 3: Successful Paper and Grant Writing -- 14. Writing a successful research paper. I -- Up to the point of submission -- 15. Writing a successful research paper. II -- Revising, resubmitting, and post-acceptance tasks -- 16. Funding: An overview -- 17. Where to apply for funding: making the right choices -- 18. Writing a winning grant application -- 19. Grant budgeting -- 20. Grant writing: Pearls and lumps of coal -- 21. Research Training, Fellowship, and Career grants -- 22. Grant review from the inside -- 23. Interpreting your reviews -- 24. To resubmit or not resubmit and how to do it -- Part 4: Good presentations, conferencing, networking, and other useful tools -- 25. The art of good presentation -- 26. Effective conferencing -- 27. Networking in the 21st century -- 28. Conflicts of interest -- 29. Scientific conduct and misconduct: what is right and proper, what is not, and what is somewhere in the middle -- 30. Article review and reading: being efficient and as thorough as you need to be -- 31. Patents -- 32. Working with industry -- Part 5: Career choices and life lessons -- 33. Jobs in biomedical science: seeking, landing, and changing -- 34. Academic Promotion and Titles -- 35. On being a mentor -- 36. Yardsticks of success -- 37. Research Life Lesson #1: Everything takes longer than you think, so plan for it -- 38. Research life lesson #2: A person's research is endlessly important to them -- 39. Research Life lesson #3: Balance, timing, cycles and seeing the big picture -- 40. Research Life Lesson #4: Your career is an ultramarathon, not a sprint -- 41. Conclusion: Nothing satisfies like meaningful work -- Acknowledgements.
  • 2006From: Cambridge
    Phil Dee ; with cartoons by Chris McLeod.
    pt. 1. The first couple of years -- Choosing and handling your PhD adviser -- Motivation, time management and multitasking -- Handling the literature -- Report writing -- Powerful presentations -- pt. 2. The end of the beginning -- Writing papers and abstracts -- Conferences and poster presentations -- Writing and defending your thesis -- Coping with pressure and stress -- pt. 3. The transition to postdoctoral research -- The transition from graduate student to post-doc -- Collaboration and visiting other labs -- Supervising students -- Teaching -- Writing grant proposals and fellowship applications -- pt. 4. Making it in science -- Culturing your image -- You and your big ideas -- Planning for a permanent job -- Do you have Principal Investigator (PI) potential?
  • 2007From: Springer
    edited by Stanley P.L. Leong.
    Historical perspective and evolving concerns for human research / Bernard Lo and Nesrin Garan -- Cancer trials and the Institutional Review Board (IRB) / Scott Kurtzman and Zita Lazzarini -- NCI's cancer therapy evaluation program: a commitment to treatment trials / Jeffrey S. Abrams, Anthony Murgo and Michaele C. Christian -- Practical guide for cancer clinical investigators / Steven Hirschfeld -- The role of cooperative groups in cancer clinical trials / Ann M. Mauer, Elizabeth S. Rich and Richard L. Schilsky -- The advocate role in clinical study development and partnering with patient advocates in your local institution / Barbara Parker -- The National Breast Cancer Coalition: setting the standard for advocate collaboration in clinical trials / Fran Visco -- The role of the principal investigator in cancer clinical trials / Stanley P.L. Leong -- The audit process and how to ensure a successful audit / Y. Nancy You, Lisa Jacobs, Elizabeth Martinez and David M. Ota -- The privacy rule (HIPAA) as it relates to clinical research / John M. Harrelson and John M. Falletta -- The Commission on Cancer, American College of Surgeons' response to HIPAA / E. Greer Gay -- Ethical and legal issues in the conduct of cancer clinical trials / Gerianne J. Sands and Peggy A. Means -- The role of the Office of Research Integrity in cancer clinical trials / Peter Abbrecht, Nancy Davidian, Samuel Merrill and Alan R. Price -- Strategies for the administration of a clinical trial infrastructure: lessons from a comprehensive cancer center / Leonard A. Zwelling and Carleen A Brunelli -- The clinical research process: building a system in harmony with its users / Greg Koski -- Cancer research and clinical trial in action: an important exercise before you embark on your study / Stanley P.L. Leong, Larry Carbone and Scott Kurtzman.
    Also available: Print – 2007
  • 2016From: Springer
    Daniela Cristina Stefan, editor.
    1.Introduction: the need to conduct cancer research in developing countries -- 2.Steps of a research study: from research question to publication -- 3.Types of research designs -- 4.Clinical research in developing countries: An overview -- 5.The research protocol -- 6.Ethics of conducting cancer research in developing countries -- 7.Data management and statistics -- 8.Funding For Cancer Research and Clinical Studies in Low and Middle-Income Countries -- 9.International Collaboration in Cancer Research -- 10.Publication and dissemination of research findings.
  • 2006From: NLM
    NLM Board of Regents.
  • 2007From: NCBI Bookshelf
    Karen Patrias ; Daniel L. Wendling, technical editor.
    Citing Published Print Documents -- 1. Journals -- 2. Books -- 3. Conference Publications -- 4. Scientific and Technical Reports -- 5. Dissertations and Theses -- 6. Bibliographies -- 7. Patents -- 8. Newspaper Articles -- 9. Maps -- 10. Legal Documents -- Citing Unpublished Material -- 11. Forthcoming ("in press") -- 12. Papers and Poster Sessions Presented at Meetings -- 13. Letters and Other Personal Communication -- 14. Manuscripts -- Citing Audio and Visual Media (audiocassettes, videocassettes, slides, photographs, etc.) -- 15. Books and Other Individual Titles in Audiovisual Formats -- 16. Journals in Audiovisual Formats -- 17. Prints and Photographs -- Citing Material on CD-ROM, DVD, or Disk -- 18. Books and Other Individual Titles on CD-ROM, DVD, or Disk -- 19. Journals on CD-ROM, DVD, or Disk -- 20. Databases on CD-ROM, DVD, or Disk -- 21. Computer Programs on CD-ROM, DVD, or Disk -- Citing Material on the Internet (Online) -- 22. Books and Other Individual Titles on the Internet -- 23. Journals on the Internet -- 24. Databases/Retrieval Systems on the Internet -- 25. Web Sites -- 26. Electronic Mail and Discussion Forums -- Appendixes -- Appendix A: Abbreviations for Commonly Used English Words in Journal Titles -- Appendix B: Additional Sources for Journal Title Abbreviations -- Appendix C: Abbreviations for Commonly Used English Words in Bibliographic Description -- Appendix D: ISO Country Codes for Selected Countries -- Appendix E: Two-Letter Abbreviations for Canadian Provinces and Territories and U.S. States and Territories -- Appendix F: Notes for Citing MEDLINE® /PubMed® -- Appendix: Content Updates.
  • 2009From: ScienceDirect
    2009From: ClinicalKey
    edited by David Robertson, Gordon H. Williams.
  • 2006From: Ovid
    R. Brian Haynes, David L. Sackett, Gordon H. Guyatt, Peter Tugwell.
    Forming research questions -- Conducting systematic reviews -- Finding information about the burden of disease -- An introduction to performing therapeutic trials -- The tactics of performing therapeutic trials -- The principles behind the tactics of performing therapeutic trials -- Testing quality improvement interventions -- Evaluating diagnostic tests -- Determining prognosis and creating clinical decision rules -- Assessing claims of causation -- Generating outcome measurements, especially for quality of life -- Becoming a successful clinician-investigator -- Preparing a research protocol to improve its chances for success -- Online data collection -- Analyzing data -- Preparing reports for publication and responding to reviewers' comments -- Dealing with the media.
    Also available: Print – 2006
  • 2015From: Springer
    John G. Brock-Utne.
    This book provides insights into how to be a productive clinical researcher via real-life case examples of successful clinical research -- and also clinical research gone awry. Through these examples of success and failure, the book develops a blueprint for building a career in clinical research. Future medical practice depends on the quality of the clinical trials to which drugs, devices, and treatment procedures are subjected today. However, clinical trials are not easy to do, and many physicians and health care providers who attempt clinical research struggle in this endeavor, primarily because of lack of instruction. Clinical Research aims to fill the gap between training and research through case studies of a long-time clinical researcher's rich and varied experiences.
  • 2009From: Thieme Book
    edited by Mohit Bhandari, Anders Joensson.
    Why we need clinical research -- Historical perspectives of clinical research -- Evidence-based surgery defined -- Myths and misconceptions about evidence-based medicine -- Becoming an evidence-based surgeon -- Principles of clinical research -- Various research design classifications -- Hierarchy of research studies: from case series to meta-analyses -- Randomized and nonrandomized studies -- Understanding research study design -- Clinical case series -- Case-control study -- Prospective cohort study -- Randomized trial -- Meta-analysis -- Economic analysis -- Diagnostic study -- Reliability study -- Understanding outcomes measurement -- Classification of outcomes -- What makes an outcome measure useful -- Common generic outcome scales for surgeons -- Common disease-specific outcome scales for surgeons -- Understanding treatment effects -- Common ways to present treatment effects -- Confidence interval defined -- P value defined -- Errors in hypothesis testing -- Clinical versus statistical significance -- Practice of clinical research -- Planning a research study -- Requirements of a clinical research proposal -- Identification of a good research question -- How to conduct a comprehensive literature search -- Guide to planning a randomized trial -- Guide to planning a nonrandomized study -- Study sample size -- How to budget for a research study -- Research ethics, review boards, and consent forms -- Regulatory issues in the evaluation of a new device or drug -- Strategies in research funding -- Conducting a research study -- Roles of the research team -- Role of a central methods center -- Role of a data monitoring committee -- Need for separate adjudication of outcomes -- Data management -- Study case report forms -- Study manual of operations -- Review of basic statistical principles -- Statistical means and proportions -- Regression analysis -- Analysis of variance -- Correlation defined.
  • 2012From: Springer
    Rachel L. Richesson, James E. Andrews, editors.
    "This book provides foundational coverage of key areas, concepts, constructs, and approaches of medical informatics as it applies to clinical research activities, in both current settings and in light of emerging policies. The field of clinical research is fully characterized (in terms of study design and overarching business processes), and there is emphasis on information management aspects and informatics implications (including needed activities) within various clinical research environments. The purpose of the book is to provide an overview of clinical research (types), activities, and areas where informatics and IT could fit into various activities and business practices. This book introduces and applies informatics concepts only as they have particular relevance to clinical research settings"--Provided by publisher.
  • 2013From: ProQuest Ebook Central
    R. Jennifer Cavalieri, Mark E. Rupp.
    Introduction to research -- Site administration -- Managing financial processes -- Managing regulatory activities and documents -- Managing clinical trial activities -- Managing data and research records -- Conclusions and final remarks.
  • 2006From: Springer
    edited by David F. Penson, John Wei.
    Planning the research / Eugene Blackstone -- Ethical issues in clinical research / David F. Penson -- Budget development and staffing / Judith Fine and Peter C. Albertsen -- Non randomized interventional study designs (quasi-experimental designs) / David Axelrod, Rodney Hayward -- Randomized clinical trials of surgical procedures / Michael P. Porter -- Use of observational databases (registries) in research / Deborah P. Lubeck -- Risk adjustment / William G. Henderson and Shukri F. Khuri -- Basic statistical methods / David Etzioni, Nadia Howlader, and Ruth Etzioni -- Survival analyses / Rodney L. Dunn and John T. Wei -- Assessing the performance and validity of diagnostic tests and screening programs / David C. Miller, Rodney L. Dunn, and John T. Wei -- Secondary data analyses / Andrew Rosenberg, MaryLou VH Greenfield, and Justin B. Dimick -- Traditional outcome measures / Aruna V. Sarma, and Julie C. McLaughlin -- Health-related quality of life / Mark Litwin -- Measuring patient satisfaction / Arvin Koruthu George and Martin G. Sanda -- Quality of care / Jessica B. O'Connell and Clifford Y. Ko -- Cost-effectiveness analyses / Lynn Stothers -- Qualitative research / Donna L. Berry, Sally L. Maliski, and William J. Ellis -- Systematic reviews and meta-analyses / Timothy J. Wilt and Howard A. Fink.
  • 2011From: CRCnetBASE
    Karl E. Peace, Ding-Geng (Din) Chen.
    "Now viewed as its own scientific discipline, clinical trial methodology encompasses the methods required for the protection of participants in a clinical trial and the methods necessary to provide a valid inference about the objective of the trial. Drawing from the authors courses on the subject as well as the first authors more than 30 years working in the pharmaceutical industry, Clinical trial methodology emphasizes the importance of statistical thinking in clinical research and presents the methodology as a key component of clinical research. From ethical issues and sample size considerations to adaptive design procedures and statistical analysis, the book first covers the methodology that spans every clinical trial regardless of the area of application. Crucial to the generic drug industry, bioequivalence clinical trials are then discussed. The authors describe a parallel bioequivalence clinical trial of six formulations incorporating group sequential procedures that permit sample size re-estimation. The final chapters incorporate real-world case studies of clinical trials from the authors own experiences. These examples include a landmark Phase III clinical trial involving the treatment of duodenal ulcers and Phase III clinical trials that contributed to the first drug approved for the treatment of Alzheimers disease. Aided by the U.S. FDA, the U.S. National Institutes of Health, the pharmaceutical industry, and academia, the area of clinical trial methodology has evolved over the last six decades into a scientific discipline. This guide explores the processes essential for developing and conducting a quality clinical trial protocol and providing quality data collection, biostatistical analyses, and a clinical study report, all while maintaining the highest standards of ethics and excellence"--Provided by publisher.
  • 2006From: Springer
    edited by MaryAnn Foote.
  • 2011From: Springer
    Holly H.C. Kimko, Carl C. Peck, editors.
    This edition includes both updates and new uses and issues concerning CTS, along with case studies of how clinical trial simulations are being applied in various therapeutic and application areas. Importantly, the book expands on the utility of CTS for informing decisions during drug development and regulatory review. Each chapter author was selected on the basis of demonstrated expertise in state-of-the-art application of CTS. The target audience for this volume includes researchers and scientists who wish to consider use of simulations in the design, analysis, or regulatory review and guidance of clinical trials. This book does not embrace all aspects of trial design, nor is it intended as a complete recipe for using computers to design trials. Rather, it is an information source that enables the reader to gain understanding of essential background and knowledge for practical applications of simulation for clinical trial design and analysis. It is assumed that the reader has a working understanding of pharmacokinetics and pharmacodynamics, modeling, pharmacometric analyses, and/or the drug development and regulatory processes.
  • 2016From: ClinicalKey
    Tom Brody.
    1. Origins of drugs -- 2. Clinical trial design -- 3. Run-in period -- 4. Inclusion/exclusion criteria, stratification, and subgroups -- part I -- 5. Inclusion/exclusion criteria, stratification, and subgroups -- part II -- 6. Blinding, randomization, and allocation -- 7. Placebo arm as part of clinical trial design -- 8. Intent-to-treat analysis versus per protocol analysis -- 9. Biostatistics -- part I -- 10. Biostatistics -- part II -- 11. Introduction to endpoints -- 12. Oncology endpoint -- objective response -- 13. Oncology endpoints : overall survival and progression-free survival -- 14. Oncology endpoints : time to progression -- 15. Oncology endpoint : disease-free survival -- 16. Oncology endpoint : time to distant metastasis -- 17. Neoadjuvant therapy versus adjuvant therapy -- 18. Hematological cancers -- 19. Biomarkers -- 20. Endpoints for immune diseases -- 21. Endpoints for infections -- 22. Health-related quality of life tools -- oncology -- 23. Health-related quality-of-life tools -- immune disorders -- 24. Health-related quality-of-life tools -- infections -- 25. Drug safety -- 26. Mechanism of action of diseases and drugs -- part I -- 27. Mechanism of action -- part II (cancer) -- 28. Mechanism of action -- part III (immune disorders) -- 29. Mechanisms of action -- part IV (infections) -- 30. Consent forms -- 31. Package inserts -- 32. Warning letters -- 33. Regulatory approval -- 34. Patents.
  • 2012From: ScienceDirect
    Tom Brody.
    The origins of drugs -- Introduction to regulated clinical trials -- Run in period -- Inclusion/exclusion criteria, stratification, and subgroups : part I -- Inclusion and stratification criteria : part II -- Randomization, allocation, and blinding -- Placebo arm as part of clinical study design -- Intent to treat analysis vs. per protocol analysis -- Biostatistics -- Introduction to endpoints for clinical trials in pharmacology -- Endpoints in clinical trials on solid tumors : objective response -- Oncology endpoints : overall survival and progression free survival -- Oncology endpoints : time to progression -- Oncology endpoint : disease free survival -- Oncology endpoint : time to distant metastasis -- Neoadjuvant therapy versus adjuvant therapy -- Hematological cancers -- Biomarkers and personalized medicine -- Endpoints in immune diseases -- Endpoints in clinical trials on infections -- Health related quality of life -- Health related quality of life instruments for immune disorders -- Health related quality of life instruments and infections -- Drug safety -- Mechanism of action : part I -- Mechanism of action, part II : cancer -- Mechanism of action, part III : immune disorders -- Mechanisms of action, part IV : infections -- Consent forms -- Package inserts -- Regulatory approval -- Patents.
  • 2012From: Wiley
    Curtis L. Meinert.
    A thoroughly updated new edition of the essential reference on the design, practice, and analysis of clinical trials. "Clinical trials dictionary : terminology and usage recommendations", Second Edition presents clear, precise, meticulously detailed entries on allaspects of modern-day clinical trials. Written and compiled by one of the world's leading clinical trialists, this comprehensive volume incorporates areas of medicine, statistics, epidemiology, computer science, and bioethics - providing a treasure trove of key terms and ideas.
  • 2013From: Wiley
    Curtis L. Meinert.
  • 2014From: Wiley
    Michael O'Kelly, Bohdana Ratitch.
    "This book provides practical guidance for statisticians, clinicians, and researchers involved in clinical trials in the biopharmaceutical industry, medical and public health organisations. Academics and students needing an introduction to handling missing data will also find this book invaluable. The authors describe how missing data can affect the outcome and credibility of a clinical trial, show by examples how a clinical team can work to prevent missing data, and present the reader with approaches to address missing data effectively. The book is illustrated throughout with realistic case studies and worked examples, and presents clear and concise guidelines to enable good planning for missing data. The authors show how to handle missing data in a way that is transparent and easy to understand for clinicians, regulators and patients. New developments are presented to improve the choice and implementation of primary and sensitivity analyses for missing data. Many SAS code examples are included - the reader is given a toolbox for implementing analyses under a variety of assumptions"--Provided by publisher.
  • editors, Julian P.T. Higgins and Sally Green.
    "The Cochrane Handbook for Systematic Reviews of Interventions (the Handbook) provides guidance to authors for the preparation of Cochrane Intervention reviews (including Cochrane Overviews of reviews)." "The Handbook is updated regularly to reflect advances in systematic review methodology and in response to feedback from users. Please refer to the web site for the most recent version, for interim updates to the guidance and for details of previous versions of the Handbook."
  • 2010From: ProQuest Safari
    Glenn A. Walker, Jack Shostak.
    Introduction & basics -- Topics in hypothesis testing -- The data set TRIAL -- The one-sample t-test -- The two-sample t-test -- One-way ANOVA -- Two-way ANOVA -- Repeated measures analysis -- The crossover design -- Linear regression -- Analysis of covariance -- The Wilcoxon signed-rank test -- The Wilcoxon rank-sum test -- The Kruskal-Wallis test -- The binomial test -- The Chi-square test -- Fisher's exact test -- McNemar's test -- The Cochran-Mantel-Haenszel test -- Logistic regression -- The log-rank test -- The Cox proportional hazards model -- Exercises.
    Also available: Print – 2010
  • Maureen M. Dawson, Brian A. Dawson, Joyce A. Overfield.
    PrintStatus: Not Checked OutLane Catalog Record
    Communication skills in science -- Using scientific literature -- Essay writing -- Writing practical reports -- The project report -- Scientific posters -- Oral presentations -- Preparing a curriculum vitae and job application.
  • 2011From: ProQuest Safari
    by Waddy Thompson.
    The Practice of Grant Writing -- The ABCs of Grants -- A Foundation Primer -- A Corporation Primer -- A Government Primer -- An Individual Donor Primer -- You Can Find It Online -- You Can Find It Offline -- Narrowing Your Prospects -- Sow Before You Reap -- Testing the Waters -- Planning for Success, Now and Tomorrow -- The Parts of a Grant Proposal -- Selling Your Project -- Dollars and Cents -- The Cover Letter and Executive Summary -- Repute and Tribute -- Putting It All Together -- Other Types of Applications -- Waiting for and Receiving the Verdict -- Reporting on Success -- Advice for Individual Grant Seekers -- Working as a Freelance Grant Writer -- The Business Side of Freelancing.
  • 2011From: CRCnetBASE
    Shein-Chung Chow.
    "Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice"--Provided by publisher.
  • 2013From: NAP
    Committee to Review the Clinical and Translational Science Awards Program at the National Center for Advancing Translational Sciences, Board on Health Sciences Policy, Institute of Medicine of The National Academies ; Alan I. Leshner, Sharon F. Terry, Andrea M. Schultz, and Catharyn T. Liverman, editors.
    This report provides the IOM committee's findings and recommendations regarding the progress and potential of NIH's CTSA Program. The report covers the breadth of the statement of task and highlights opportunities to bolster the program and ensure its continued success and sustainability in supporting clinical and translational researchers and serving the needs of the communities CTSAs are linked to and in which they reside. Chapter 2 discusses the ecosystem in which NCATS and the CTSA Program operate and provides the committee's vision for the next phase of the CTSA Program. Chapter 3 emphasizes the need for strong and active leadership by NCATS in establishing a clear vision and mission for the program along with measurable goals; supporting individual CTSAs; partnering and collaborating within the NIH and with external partners; and evaluating and communicating the program's value. Chapter 4 highlights specific opportunities and priorities in the areas of training and education, community engagement, and research related to child health. On the basis of discussions, conclusions, and recommendations outlined in the preceding chapters, in Chapter 5 the report concludes with next steps and potential future directions.
  • 2009From: CRCnetBASE
    Jay Herson.
    Introduction -- Organization of a safety monitoring program for a confirmatory trial -- Meetings -- Clinical issues -- Statistical issues -- Bias and pitfalls -- Data monitoring committee decisions -- Emerging issues.
  • 2006From: Springer
    David L. DeMets, Curt D. Furberg, Lawrence M. Friedman, editors.
    Also available: Print – 2006
  • 2014From: Wiley
    Shein-Chung Chow, Jen-Pei Liu.
    pt. I. Introduction -- Basic statistical concepts -- Basic design considerations -- Randomization and blinding -- pt. II. Designs and their classifications -- Designs for clinical trials -- Designs for cancer clinical trials -- Classification of clinical trials -- pt. III. Analysis of clinical data -- Analysis of continuous data -- Analysis of categorical data -- Censored data and interim analysis -- Sample size determination -- pt. IV. Issues in evaluation -- Issues in efficacy evaluation -- Safety assessment -- pt. V. Recent development -- Biomarkers and targeted clinical trials -- Trials for evaluating accuracy of diagnostic devices -- Statistical methods in translational medicine -- Adaptive clinical trial designs -- Traditional Chinese medicine -- pt. VI. Conduct of clinical trials -- Preparation and implementation of a clinical protocol -- Data management of a clinical trial.
  • 2009From: CRCnetBASE
    edited by Karl E. Peace.
    Overview of time-to-event endpoint methodology / Karl E. Peace -- Design (and monitoring) of clinical trials with time-to-event endpoints / Michael W. Sill and Larry Rubinstein -- Overview of time-to-event parametric methods / Karl E. Peace and Kao-Tai Tsai -- Overview of semiparametric inferential methods for time-to-event endpoints / Jianween Cai and Donglin Zeng -- Overview of inferential methods for categorical time-to-event data / Eric V. Slud -- Overview of Bayesian inferential methods including time-to-event endpoints / Laura H. Gunn -- An efficient alternative to the Cox model for small time-to-event trials / Devan V. Mehrotra and Arthur J. Roth -- Estimation and testing for change in hazard for time-to-event endpoints / Rafia Bhore and Mohammad Huque -- Overview of descriptive and graphical methods for time-to-event data / Michael O'Connell and Bob Treder -- Design and analysis of analgesic trials / Akiko Okamoto, Julia Wang, and Surya Mohanty -- Design and analysis of analgesic trials with paired time-to-event endpoints / Zhu Wang and Hon Keung Tony Ng -- Time-to-event endpoint methods in antibiotic trials / Karl E. Peace -- Design and analysis of cardiovascular prevention trials / Michelle McNabb and Andreas Sashegyi -- Design and analysis of antiviral trials / Anthony C. Segreti and Lynn P. Dix -- Cure rate models with applications to melanoma and prostate cancer data / Ming-Hui Chen and Sungduk Kim -- Parametric likelihoods for multiple nonfatal competing risks and death, with application to cancer data / Peter F. Thall and Xuemei Wang -- Design, summarization, analysis, and interpretation of cancer prevention trials / Matthew C. Somerville, Jennifer B. Shannon, and Timothy H. Wilson -- LASSO method in variable selection for right-censored time-to-event data with application to astrocytoma brain tumor and chronic myelogonous leukemia / Lili Yu and Dennis Pearl -- Selecting optimal treatments based on predictive factors / Eric C. Polley and Mark J. van der Laan -- Application of time-to-event methods in the assessment of safety in clinical trials / Kelly L. Moore and Mark J. van der Laan -- Design and analysis of chronic carcinogenicity studies of pharmaceuticals in rodents / Mohammad Atiar Rahman and Karl K. Lin -- Design and analysis of time-to-tumor response in animal studies : a Bayesian perspective / Steve Thomson and Karl K. Lin.
  • 2012From: Wiley
    Gerald van Belle, Kathleen F. Kerr.
    Design and Analysis of Experiments in the Health Sciences; Contents; Preface; 1 The Basics; 1.1 Four Basic Questions; 1.2 Variation; 1.3 Principles of Design and Analysis; 1.4 Experiments and Observational Studies; 1.5 Illustrative Applications of Principles; 1.6 Experiments in the Health Sciences; 1.7 Adaptive Allocation; 1.7.1 Equidistribution; 1.7.2 Adaptive Allocation Techniques; 1.8 Sample Size Calculations; 1.9 Statistical Models for the Data; 1.10 Analysis and Presentation; 1.10.1 Graph the Data in Several Ways; 1.10.2 Assess Assumptions of the Statistical Model.
  • 2010From: CRCnetBASE
    Diane L. Fairclough.
    Using SAS, SPSS, and R, this book addresses design and analysis aspects in enough detail so that readers can apply statistical methods to their own longitudinal studies. This edition includes a new chapter on testing models that involve moderation and mediation, a new chapter on QALYs and QTWiST specific to clinical trials, and recent methodological developments for the analysis of trials with missing data. It also presents revised discussions of multiple comparisons procedures that focus on the integration of HRQoL outcomes with other study outcomes using gatekeeper strategies.
  • John W. Creswell, Vicki L. Plano Clark.
    "Combining the latest thinking about mixed methods research designs with practical, step-by-step guidance, the Second Edition of Designing and Conducting Mixed Methods Research now covers six major mixed methods designs. Authors John W. Creswell and Vicki L. Plano Clark walk readers through the entire research process, from formulating questions to designing, collecting data, and interpreting results and include updated examples from published mixed methods studies drawn from the social, behavioral, health, and education disciplines."--pub. desc.
  • 2007From: Ovid
    [edited by] Stephen B. Hulley ... [et al.].
    Designing a randomized blinded trial / Steven R. Cummings, Deborah Grady, and Stephen B. Hulley -- Alternative trial designs and implementation issues / Deborah Grady, Steven R. Cummings, and Stephen B. Hulley -- Designing studies of medical tests / Thomas B. Newman ... [et al.] -- Utilizing existing databases / Deborah Grady and Norman Hearst -- Addressing ethical issues / Bernard Lo -- Designing questionnaires and interviews / Steven R. Cummings and Stephen B. Hulley -- Data management / Michael A. Kohn -- Implementing the study and quality control / Deborah Grady and Stephen B. Hulley -- Community and international studies / Norman Hearst and Thomas E. Novotny -- Writing and funding a research proposal / Steven R. Cummings and Stephen B. Hulley. Getting started: the anatomy and physiology of clinical research / Stephen B. Hulley, Thomas B. Newman, and Steven R. Cummings -- Conceiving the research question / Steven R. Cummings, Warren S. Browner, and Stephen B. Hulley -- Choosing the study subjects: specification, sampling, and recruitment / Stephen B. Hulley, Thomas B. Newman, and Steven R. Cummings -- Planning the measurements: precision and accuracy / Stephen B. Hulley, Jeffrey N. Martin and Steven R. Cummings -- Getting ready to estimate sample size: hypotheses and underlying principles / Warren S. Browner, Thomas B. Newman, and Stephen B. Hulley -- Estimating sample size and power: applications and examples / Warren S. Browner, Thomas B. Newman, and Stephen B. Hulley -- Designing a cohort study / Steven R. Cummings, Thomas B. Newman, and Stephen B. Hulley -- Designing cross-sectional and case-control studies / Thomas B. Newman ... [et al.] -- Enhancing causal inference in observational studies / Thomas B. Newman, Warren S. Browner, and Stephen B. Hulley --
    Also available: Print – 2007
  • 2012From: Springer
    David Harrington, editor.
  • 2006From: NAP
    Committee on Clinical Trial Registries, Board on Health Sciences Policy.
  • 1999From: Wiley
    Simon Day.
  • edited by Errol C. Friedberg and Philip C. Hanawalt.
    PrintStatus: Not Checked OutLane Catalog Record
  • 2008From: Springer
    edited by Pranee Liamputtong.
  • 2011From: CRCnetBASE
    Ying Kuen Cheung.
    Part I. Fundamentals -- Chapter 1. Introduction -- Chapter 2. Dose Finding in Clinical Trials -- Chapter 3. The Continual Reassessment Method -- Chapter 4. One-Parameter Dose-Toxicity Models -- Chapter 5. Theoretical Properties -- Chapter 6. Empirical Properties -- Part II. Design Calibration -- Chapter 7. Specifications of a CRM Design -- Chapter 8. Initial Guesses of Toxicity Probabilities -- Chapter 9. Least Informative Normal Prior -- Chapter 10. Initial Design -- Part III. CRM and Beyond -- Chapter 11. The Time-to-Event CRM -- Chapter 12. CRM with Multiparameter Models -- Chapter 13. When the CRM Fails -- Chapter 14. Stochastic Approximation.
  • 2010From: Karger
    editors, Berthold Koletzko, Sibylle Koletzko, Frank Rümmele.
    Innovations in infant milk feeding : from the past to the future / Koletzko, B. -- Novel insights into human lactation as a driver of infant formula development / Lønnerdal, B. -- The clinical challenge of preventing and treating malnutrition / Cooper, P.A. -- Progress of enteral feeding practice over time : moving from energy supply to patient-and disease-adapted formulationse / Koletzko, S. -- Molecular mechanisms of pediatric nutrition / Rümmele, F. -- Epidemiological research drives a paradigm shift in complementary feeding : the celiac disease story and lessons learnt / Nordyke, K. ... [et al.] -- Technological progress as a driver of innovation in infant foods / Ferruzzi, M.G.; Neilson, A.P. -- Health economic perspectives of pediatric malnutrition : determinants of innovative progress / Spieldenner, J. -- Economic perspectives on pediatric obesity : impact on health care expenditures and cost-effectiveness of preventive interventions / John, J. -- Sustainable clinical research, health economic aspects, and marketing : drivers of product innovation / Haschke, F.; Klassen-Wigger, P. -- Evaluation of dietetic product innovations : the relative role of preclinical and clinical studies / Makrides, M.; Gibson, R.A. -- Regulatory environment and claims : limits and opportunities / Martin, A. -- The role of consumers / Raats, M.M. -- Bioethics and innovation in pediatric nutrition research / Solomons, N.W. -- The role of pediatricians as innovators in pediatric nutrition / Greer, F.R. -- Promoting innovation in pediatric nutrition / Bier, D.M.
  • 2005From: Springer
    edited by Berthold Koletzko, Peter Dodds, Hans Akerblom and Margaret Ashwell.
    What is the EU infant nutrition cluster? -- Early nutrition and its later consequences: new opportunities -- The developmental origins of adult health and well-being -- Long term effects of breastfeeding on the infant and mother -- Experimental evidence for long-term programming effects of early diet -- Candidate genes for obesity--how might they interact with environment and diet? -- Rate of growth in early life: a predictor of later health? -- Protective effect of breast-feeding against obesity in childhood-- Discussion forum: from innovation to implementation -- Challenges and opportunities in pan-European collaboration for researchers from Central and Eastern Europe -- Best practice in communicating the results of European research to the public -- Longterm effects of pre- and postnatal exposure to low and high dietary protein levels / Cornelia C. Metges -- Protein intake in the first year of life: a risk factor for later obesity? -- The role of long-chain poly-unsaturated fatty acids (LCPUFA) in growth and development -- Experimental models for studying perinatal lipid metabolism -- Effect of N-3 polyunsaturated fatty acid supplementation in pregnancy: the Nuheal trial -- Young researchers' workshop -- Consumer needs regarding dietetic products for pregnant and lactating women and for baby foods -- Focus group: breakfast meeting: SMES and their co-operation with academia -- Ethical issues in perinatal nutrition research -- Early programming of diabetes risk--an introduction -- Early nutrition and later diabetes risk -- Is type 1 diabetes a disease of the gut immune system triggered by cow's milk insulin? -- Gluten-free diet in subjects at risk for type 1 diabetes: a tool for delaying progression to clinical disease? -- Insulin like growth factor regulation of body mass in breastfed and milk formula fed infants -- Inverse association between trans isomeric and long-chain polyunsaturated fatty acids in erythrocyte membrane lipids in pregnant women -- Comparison of essential fatty acid status among German, Hungarian and Spanish women at mid-gestation -- Trans isomeric fatty acids as confounding variables in studies on perinatal LC-PUFA supply -- An eight years prospective study of iron deficiency anaemia in infancy -- New insights in the potential mechanism of action of nucleotides to modulate immunity -- Thriving of malnourished breastfed infants after additional formula milk feeding -- Role of mammary gland lipoprotein lipase in the availablilty of polyunsaturated fatty acids for milk synthesis -- Is the crying behaviour in infants up to the age of 3 months influenced by the type of early nutrition? -- Dietary gangliosides: beneficial effects for the neonate and potential mechanism of action -- Leptin in breast-fed and formula-fed infants -- Dietary fatty acids during pregnancy determines maternal fatty acid profile during late pregnancy and their availability to the fetus even during fasting condtions -- Effects of oil-supplemented diets on liver expression of PPAR alpha-related genes in pregnant rats -- Effect of a new infant formula enriched with prebiotics, probiotics, nucleotides and LC-PuFA on recovery after infection -- Does habitual protein intake in early childhood influence age and body mass index at adiposity rebound? -- Dietary compliance in diabetes prevention project in Finland -- Changes of plasma fatty acid profile and antioxidant vitamins during normal pregnancy -- Optimal design for the recruitment of participants as a factor for the effective implementation of a clinical trial -- The effect of ponderal index on plasma concentration of insulin-like growth factor-1 (IGF-1) in neonatal pigs -- Effects of prenatal exposure to low and high dietary protein levels on maternal and fetal amino acid metabolism in rats -- Cow's milk introduction in Spanish infants -- Longer term effects of early cholesterol intake on cholesterol biosynthesis and plasma lipids: a randomized clinical trial -- Patterns of growth and energy utilization of the diet after a period of dietary restriction during the weaning period -- Infant formula feeding pattern and weaning introduction in Spanish infants -- Visual evoked potentials in infants after dietary supply of docosahexaenoic acid and 5-methyltetrahydrofolate during pregnancy -- Electronic data capture and use of internet technologies in a double-blind randomised intervention trial -- Breastfeeding and baby friendly hospital initiative in Slovenia -- Nutritional status in young adults with screen-detected silent/sub-clinical coeliac disease -- Liporotein lipase (LPL) MRNA expression in placentas from normal and IUGR (intrauterine growth restricted) pregnancies by real-time PCR -- Maternal fasting effect on neonatal health -- The quality of schoolchildren's nutrition in Serbia -- Tendency towards obesity in Sydney school children -- Monitoring and supervising a dietary intervention trial using modern data processing system -- Analysis of drop-outs in a longitudinal study -- Recruitment strategies of the Spanish group in the "EU childhood obesity: programming by infant nutrition" -- Diet and nutritional risk factors in schoolchildren -- Influence of two forms of caseinophosphopeptide on iron bio availability -- Model of childhood obesity primary prevention programme -- Problems related to recruitment of participants for the triger project -- Vitamin D status at birth in Brussels--preliminary results -- Obesity among young adolescent Kuwaitis -- Dynamic changes in adiposity from fetal to postnatal life are involved in the adult metabolic syndrome associated with reduced fetal growth -- Excess fetal adiposity is associated with programming of placental lipid genes -- Appetite control in breastfed and formula fed infants -- What are the Danone Institutes.
    Also available: Print – 2005
  • 2009From: Springer
    Paul Smeyers, Marc Depaepe, editors.
  • sous la direction de Jean-Gaël Barbara & Pierre Corvol.
  • Catherine Brady.
    PrintStatus: Not Checked OutLane Catalog Record
    A certain sense of self -- Shedding encumbrances -- One of Gall's gals -- Revelations -- Opportunism -- Gold rush -- Entering the fray -- An interlocking system -- Dr. Jekyll or Mr. Hyde? -- Members of a guild -- Citizen scientist -- Political fallout -- "You have to think it's fun" -- Notes -- Bibliography.
  • 2009From: Springer
    Ramón Ribes, Palma Iannarelli, Rafael F. Duarte.
  • 2012From: Springer
    O.S. Miettinen, I. Karp.
    Epidemiology: Grappling with the Concept -- Epidemiological Knowledge: Examples -- Etiology as a Pragmatic Concern -- Etiology as the Object of Study -- Etiologic Studies' Essentials -- Etiologic Studies' Typology -- Etiologic Studies' Objects Design -- Etiologic Studies' Methods Design -- Etiologic Studies' Intervention Counterparts -- Causal Studies' Acausal Counterparts -- Studies on Screening for a Cancer -- Some Paradigmatic Studies -- From Studies to Knowledge -- Fact-finding in Epidemiological Practice.
  • 2013From: Wiley
    editor, Phil Langton.
    This concise, easy-to-follow text gives an insight into core techniques and practices in biomedical research and how, when and why a technique should be used and presented in the literature. Readers are alerted to common failures and misinterpretations that may evade peer review and are equipped with the judgment necessary to be properly critical of the findings claimed by research articles. --from publisher description
  • 2014From: Springer
    Stephen P. Glasser, editor.
    In its extensively revised and updated Second Edition, this book provides a solid foundation for readers interested in clinical research. Discussion encompasses genetic, pharmacoepidemiologic and implementation research. All chapters have been updated with new information and many new tables have been added to elucidate key points. The book now offers discussion on how to handle missing data when analyzing results, and coverage of Adaptive Designs and Effectiveness Designs and new sections on Comparative Effectiveness Research and Pragmatic Trials. Chapter 6 includes new material on Phase 0 Trials, expanded coverage of Futility Trials, a discussion of Medical Device approval, Off Label Drug use and the role of the FDA in regulating advertising. Additional new information includes the role of pill color and shape in association with the placebo effect and an examination of issues surrounding minority recruitment. The final chapter offers a new section on manuscript preparation along with a discussion of various guidelines being adopted by journals: CONSORT, STROBE, PRISMA, MOOSE and others; and coverage of Conflicts of Interest, Authorship, Coercive Citation, and Disclosures in Industry-Related Associations. Building on the strengths of its predecessor in its comprehensive approach and authoritative advice, the new edition offers more of what has made this book a popular, trusted resource for students and working researchers alike.
  • 2008From: Springer
    edited by Stephen P. Glasser.
    I. pt. I. Clinical Research: Definitions, "Anatomy and Physiology," and the Quest for "Universal Truth" / Stephen P. Glasser, p. 3-11 -- Introduction to Clinical Research and Study Designs / Stephen P. Glasser, p. 13-27 -- Clinical Trials / Stephen P. Glasser, p. 29-62 -- Alternative Interventional Study Designs / Stephen P. Glasser, p. 63-71 -- Postmarketing Research / Stephen P. Glasser, Elizabeth Delzell and Maribel Salas, p. 73-91 -- The United States Federal Drug Administration (FDA) and Clinical Research / Stephen P. Glasser, Carol M. Ashton and Nelda P. Wray, p. 73-110 -- The Placebo and Nocebo Effect / Stephen P. Glasser and William Frishman, p. 111-140 -- Recruitment and Retention / Stephen P. Glasser, p. 141-149 -- Data Safety and Monitoring Boards (DSMBs) / Stephen P. Glasser and O. Dale Williams, p. 151-158 -- Meta-Analysis / Stephen P. Glasser and Sue Duval, p. 159-177 -- II. pt. II. -- Research Methods for Genetic Studies / Sadeep Shrestha and Donna K. Arnett, p. 181-199 -- Research Methods for Pharmacoepidemiology Studies / Maribel Salas and Bruno Stricker, p. 201-216 -- Implementation Research: Beyond the Traditional Randomized Controlled Trial / Amanda H. Salanitro, Carlos A. Estrada and Jeroan J. Allison, p. 217-244 -- Research Methodology for Studies of Diagnostic Tests / Stephen P. Glasser, p. 245-257 -- III. pt. III. Statistical Power and Sample Size: Some Fundamentals for Clinician Researchers / J. Michael Oakes, p. 261-278 -- Association, Cause, and Correlation / Stephen P. Glasser and Gary Cutter, p. 279-294 -- Bias, Confounding, and Effect Modification / Stephen P. Glasser , p. 295-302 -- It's All About Uncertainty / Stephen P. Glasser and George Howard, p. 303-316 -- Grant Writing / Donna K. Arnett and Stephen P. Glasser, p. 317-325 -- IV. pt. IV. The Media and Clinical Research / Stephen P. Glasser, p. 329-333 -- Mentoring and Advising / Stephen P. Glasser and Edward W. Hook, p. 335-340 -- Presentation Skills: How to Present Research Results / Stephen P. Glasser, p. 341-349.
  • 2011From: Stanford Law School
    In response to a request by President Barak Obama on November 24, 2010, the Presidential Commission for the Study of Bioethical Issues oversaw a thorough fact-finding investigation into the specifics of the U.S. Public Health Service-led studies in Guatemala involving the intentional exposure and infection of vulnerable populations. Following a nine-month intensive investigation, the Commission has concluded that the Guatemala experiments involved gross violations of ethics as judged against both the standards of today and the researchers' own understanding of applicable contemporaneous practices. It is the Commission's firm belief that many of the actions undertaken in Guatemala were especially egregious moral wrongs because many of the individuals involved held positions of public institutional responsibility. The best thing we can do as a country when faced with a dark chapter is to bring it to light. The Commission has worked hard to provide an unvarnished ethical analysis to both honor the victims and make sure events such as these never happen again.
  • 2007From: Springer
    Bengt D. Furbert and Curt D. Furberg.
    Also available: Print – 2007
  • 2012From: Springer
    Pedro J. Gutiérrez Diez, Irma H. Russo, Jose Russo.
    Historical Introduction -- Descriptive Biostatistics -- Inferential Biostatistics (I): Estimating Values of Biomedical Magnitudes -- Inferential Biostatistics (II): Estimating Biomedical Behaviors -- Equations: Formulating Biomedical Laws and Biomedical Magnitudes -- Systems of Equations: The Explanation of Biomedical Phenomena (I). Basic Questions -- Systems of Equations: The Explanation of Biomedical Phenomena (II). Dynamic Interdependencies -- Optimal Control Theory: From Knowledge to Control (I). Basic Concepts -- Optimal Control Theory: From Knowledge to Control (II). Biomedical Applications -- Game Theory.
  • Jonathan Orsay.
    PrintStatus: Not Checked OutLane Catalog Record
  • 2014From: Thieme-Connect
    Hamish Simpson, Peter Augat.
  • [produced for the Sherman Fairchild Foundation by Stanford University School of Medicine].
    PrintStatus: Not Checked OutLane Catalog Record
  • 2006From: ProQuest Ebook Central
    edited by Deborah Blum, Mary Knudson, Robin Marantz Henig.
    pt. 1: Learning the craft / Mary Knudson -- Finding story ideas and sources / Philip M. Yam -- Reporting from science journals / Tom Siegfried -- Understanding and using statistics / Lewis Cope -- Writing well about science: techniques from teachers of science writing -- Taking your story to the next level / Nancy Shute -- Finding a voice and a style / David Everett -- pt. 2: Choosing your market / Carey Goldberg -- Small newspapers / Ron Seely -- Large newspapers / Robert Lee Hotz -- Popular magazines / Janice Hopkins Tanne -- Trade and science journals / Colin Norman -- Broadcast science journalism / Joe Palca -- Freelance writing / Kathryn Brown -- Science books / Carl Zimmer -- Popular audiences on the web / Alan Boyle -- Science audiences on the web / Tabitha Powledge -- Science editing / Mariette DiChristina -- pt. 3: Varying your writing style / Robin Marantz Henig -- Deadline writing / Gareth Cook -- Investigative reporting / Antonio Regalado -- Gee whiz science writing / Robert Kunzig -- Explanatory writing / George Johnson -- Narrative writing / James Shreeve -- The science essay / Robert Kanigel -- pt. 4: Covering stories in the life sciences / Deborah Blum -- Medicine / Shannon Brownlee -- Infectious diseases / Marilyn Chase -- Nutrition / Sally Squires -- Mental health / Paul Raeburn -- The biology of behavior / Kevin Begos -- Human genetics / Antonio Regalado -- pt. 5: Covering stories in the physical and environmental sciences / Deborah Blum -- Technology and engineering / Kenneth Chang -- Space science / Michael D. Lemonick -- The environment / Andrew C. Revkin -- Nature / McKay Jenkins -- Earth sciences / Glennda Chui -- Climate / Usha Lee McFarling -- Risk reporting / Cristine Russell -- Taking a different path: journalists and public information officers / the editors -- pt. 6: Communicating science from institutions / John D. Toon -- Universities / Earle Holland -- Institutional communications during crisis / Joann Ellison Rodgers -- Government agencies / Colleen Henrichsen -- Nonprofits / Frank Blanchard -- Museums / Mary Miller -- Corporate public relations / Marion Glick -- Epilogue / James Gleick.
  • 2011From: CRCnetBASE
    Andreas Wienke.
    The concept of frailty offers a convenient way to introduce unobserved heterogeneity and associations into models for survival data. In its simplest form, frailty is an unobserved random proportionality factor that modifies the hazard function of an individual or a group of related individuals. Frailty Models in Survival Analysis presents a comprehensive overview of the fundamental approaches in the area of frailty models. The book extensively explores how univariate frailty models can represent unobserved heterogeneity. It also emphasizes correlated frailty models as extensions of univariate and shared frailty models. The author analyzes similarities and differences between frailty and copula models; discusses problems related to frailty models, such as tests for homogeneity; and describes parametric and semiparametric models using both frequentist and Bayesian approaches. He also shows how to apply the models to real data using the statistical packages of R, SAS, and Stata. The appendix provides the technical mathematical results used throughout. Written in nontechnical terms accessible to nonspecialists, this book explains the basic ideas in frailty modeling and statistical techniques, with a focus on real-world data application and interpretation of the results. By applying several models to the same data, it allows for the comparison of their advantages and limitations under varying model assumptions. The book also employs simulations to analyze the finite sample size performance of the models.--From the publisher's website.
  • 2009From: Springer
    Michael Jay Katz.
  • 2007From: Springer
    Antonella Bacchieri, Giovanni Della Cioppa.
  • 2010From: Springer
    Lawrence M. Friedman, Curt D. Furberg, David L. DeMets.
    Introduction to Clinical Trials -- Ethical Issues -- What Is the Question? -- Study Population -- Basic Study Design -- The Randomization Process -- Blindness -- Sample Size -- Baseline Assessment -- Recruitment of Study Participants -- Data Collection and Quality Control -- Assessing and Reporting Adverse Events -- Assessment of Health-Related Quality of Life -- Participant Adherence -- Survival Analysis -- Monitoring Response Variables -- Issues in Data Analysis -- Closeout -- Reporting and Interpreting of Results -- Multicenter Trials.
    Also available: Print – 2010
  • Emily Ann Cox.
    This dissertation explores the impact of different types of investors on invention and innovation in new firms. While prior work has focused primarily on one type of investor, venture capitalists, and has investigated a few long-term outcomes such as exit events, I compare a variety of investor types and consider more immediate innovation-related goals. Drawing from agency and resource dependence theories, I develop and test hypotheses linking different investor types to invention and innovation in new firms. To do this, I construct a novel longitudinal dataset of 198 U.S.-based minimally invasive surgical device firms between 1986 and 2007. The findings indicate that investor type matters for both invention and innovation. Technology-focused investors promote invention while commercially-focused investors are more beneficial to innovation. I also find that although some investors (VCs) help innovation, other investors (the government's SBIR program) hurt it. This difference can be traced to investors' use of monitoring to tailor resources to the specific needs of new firms. These findings suggest that monitoring can be mutually beneficial to both parties as it allows investors to focus their efforts and new firms to receive needed resources at opportune times. My findings also suggest that new firms should be cautious, as there is a potential dark side to the relationships they form with investors: obtaining resources from some investors may prevent new firms from accomplishing their goals.
  • 2009From: CRCnetBASE
    Hinrich Göhlmann, Willem Talloen.
    "Gene expression studies merge three disciplines with different historical backgrounds: molecular biology, bioinformatics, and biostatistics. This book tears down the omnipresent language barriers among researchers of these different backgrounds by explaining the entire process of a gene expression study from conception to interpretation. It covers important technical and statistical pitfalls and problems, helping not only to explain concepts outside the domain of researchers, but to provide additional guidance in their field of expertise. The book also describes technical and statistical methods conceptually with illustrative examples, enabling those inexperienced with gene expression studies to grasp the basic principles"--Provided by publisher.
  • 2014From: Oxford Medicine Online
    Ian M. MacFarlane, Patricia McCarthy Veach, Bonnie S. LeRoy.
    Developing research questions -- Finding sources -- Writing a review of literature -- Ethics in research -- Choosing a paradigm -- Designing a quantitative study -- Quantitative data analysis : I've got data, how do I get answers? -- Conducting qualitative genetic counseling research -- Preparing a manuscript for publication -- Guidelines for directing research.
  • 2011From: Thieme Book
    edited by Mohit Bhandari, Anders Joensson.
    Why should we publish papers? / George M. Kontakis, Peter V. Giannoudis -- Presented but never published : why research papers are not being published / Cheryl Wylie, Sheila Sprague -- What is the quality of the published orthopaedic literature? / Daniel Vena, Sheila Sprague -- Common pitfalls in the reporting of surgical results / Rudolf W. Poolman -- Overview : what to consider before you start writing / Paul Karanicolas -- Ethics in writing : maintaining credibility / Lyndsay Somerville, Dianne Bryant -- Authorship : what you should know / Rad Zdero, Emil H. Schemitsch -- When do you need a statistician? : more than just number crunchers / Jason W. Busse -- The structured abstract / Ole Brink, Lars C. Borris -- Writing an introduction / Emil H. Schemitsch, Rad Zdero -- Writing a methods section / Emil H. Schemitsch, Rad Zdero -- Results : basics of analysis / Paul Karanicolas -- Results : tables, figures, and appendices / Jacquelyn Marsh, Dianne Bryant -- How to frame a discussion / Kyle Jeray, Stephanie Tanner -- Referencing and acknowledgments / Richard Gould, Bradley Petrisor -- Author instructions / George Mathew, Sheila Sprague -- Formatting your paper : title page and more / Scott Wingerter -- Grammar police : the dos and don'ts of writing / Eric Morrison -- How to address reviewer's comments : dos and don'ts / Rad Zdero, Emil H. Schemitsch -- Getting your research accepted at scientific meetings : writing the abstract / George Mathew, Sheila Sprague -- PowerPoint presentations : tips for presenting your work / Tara M. Mastracci -- Poster presentations : preparing an effective research poster / Chad Coles -- Be consistent : present and publish the same results / Boris A. Zelle.
  • 2011From: ScienceDirect
    Richard Chin, Menghis Bairu [editors].
  • 2006From: Springer
    by Maurice Kogan, Mary Henkel and Steve Hanney.
  • PrintStatus: Not Checked OutLane Catalog Record
  • Stephen W. Russell, DVM, PhD, David C. Morrison, PhD.
    Before you begin to write overview. Finding NIH funding opportunities and responding to them; How to develop an irresistible idea for your grant application; How to find the appropriate program and grant application; How to find the appropriate program and grant mechanism for your idea; Influence of the NIH review process on writing for success; Response to prior review; Create a writng schedule; The template for your research plan overview. Specific aims section: Conceptual framework for creating a bulleted outline; Writing the specific aims section; Development of the rest of your application overview. Strategic use of literature review and preliminary results; Bibliography & References cited section; Research strategy section: Significance (including scientific premise) and innovation subsections; Research strategy section: Approach subsection (Including Rigor, potential biological variables, technical preliminary studies, and renewal progress report); Senior/key person profile(s) form, biographical sketches, and multiple PD/PI leadership plan of the PHS 398 research plan form; PHS 398 modular budget form and budget justifications; SF 424 R & R [breakout] budget form and R & R subaward budget attachment(s) form; Project/performance site location(s) form; Facilities & other resources, equipment, environment impact, historical places, and foreign components sections of the R & R other project information form; Human subjects section, Vertebrate animals, select agent research, consortium/contrctual arrangements, resource sharing plan(s), Authentication of key biological and/or chemical resources, and appendix sections of the PHS 398 research plan form; SF 424 (R & R) [cover] form, the PHS 398 cover page supplement form, and the PHS assignment request form; Maximizing your application's competitiveness; How to create a compelling, informative title for your proposal; Project summary/abstract, project narrative, and proprietary/privileged information; Cover letter attachment and letters of support; Pre-supmission review and subbmission of your application; allowability of post-submission materials.
  • edited by Adele E. Clarke and Kathy Charmaz.
    PrintStatus: Not Checked OutLane Catalog Record
    v. 1. History, essential and debates in grounded theory -- v. 2. Grounded theory in disciplines and research -- v. 3. Grounded theory exemplars across disciplines -- v. 4. Situational analysis : essentials and exemplars.
  • 2012From: Springer
    Otto O. Yang.
    Overview: overall goals when writing grant applications -- Organization and use of this guide -- Preparing to write -- Types of NIH grants -- Anatomy of the NIH grant application -- Starting to write: planning the aims and overcoming writer's block -- Organization and writing style -- Figures and tables -- Specific aims -- Research strategy: significance -- Research strategy: innovation -- Research strategy: approach -- Bibliography and references cited -- Use of appendices -- Collaborators and consultants -- Training and career development grants -- Administrative sections and submission process -- Scoring process -- Resubmitting an application -- Non-NIH grants -- Conclusions.

Access restricted to Stanford community

Shortcut to Licensed Content

Lane Gateway to Licensed Content

TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.

What is it?

Lane Gateway to Licensed Content

Bookmark on Other Websites

Bookmark on Lane

  • TO INSTALL, RIGHT CLICK this button.
  • Select "Add to Favorites" (click “Continue” if you see a security alert)
  • From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
  • Once installed it will look like this
  • Click "Bookmark on Lane" to bookmark any webpage
  • Your saved bookmark will appear on this page

What is it?

Derived from Current Medical Diagnosis & Treatment, AccessMedicine's Quick Medical Diagnosis & Treatment provides topic reviews with key diagnostic and treatment features for more than 500 diseases.

A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more.

Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.

MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed Plus is a clinical information resource used to answer questions quickly at the point-of-care. Easy-to-interpret Levels of Evidence help clinicians rapidly determine the quality of the available evidence.

Biomedical and pharmacological abstracting and indexing database of published literature, by Elsevier. Embase® contains over 32 million records from over 8,500 currently published journals (1947-present) and is noteworthy for its extensive coverage of the international pharmaceutical and alternative/complementary medicine literature.

Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialties.Provides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.

Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences.

Includes cited reference searching, citation maps, and an analyze tool.

Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not.

Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.

Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.

Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities.

In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.

A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.

A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines.

Over 10,000 notes outline the status of specific infections within each country.

Large number of high quality software and database programming titles from O'Reilly. Other software titles are also available from Sams and Prentice Hall. Limited to 7 concurrent users.Vast collection of software and database programming titles from multiple publishers, including Microsoft Press.Largest provider of engineering-related eBooks; includes titles in computer science and biomedical engineering.Over 4,000 full-text e-books covering scientific and technical information from CRC Press and others. Many handbooks and single volume reference sources.Includes peer-reviewed life science and biomedical research protocols compiled from Methods in Molecular Biology, Methods in Molecular Medicine, Methods in Biotechnology, Methods in Pharmacology and Toxicology, Neuromethods, the Biomethods Handbook, the Proteomics Handbook, and Springer Laboratory Manuals.Contains full text access to selected biomedical and nursing books.

Provides online, full-text access to Springer's journal titles as well as journals from other publishers.

Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.

Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.

Stanford Medicine

Lane Medical Library